Latha Subbiah
Latha Subbiah has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Selvamani Palanisamy
Anna University
12 shared publications Selvamani Palanisamy
Department of Pharmaceutical Technology, University College of Engineering, Anna University, Bharathidasan Institute of Technology (BIT) Campus, Tiruchirappalli, India
4 shared publicationsKrishnanand Nagarajan
Anna University - BIT Campus Tiruchirappalli: Anna University Chennai - Regional Office Tiruchirappalli
3 shared publications- Prabha Thangavelu
Nandha College of Pharmacy, Affiliated with The Tamil Nadu Dr. MGR Medical University Chennai
3 shared publications Arputha Bibiana
Department of Pharmaceutical Technology, Centre for Excellence in Nanobio Translational Research, Anna University, Bharathidasan Institute of Technology Campus, Tiruchirappalli, India
2 shared publications- Christer Johansson
RISE Acreo, 40014 Göteborg, Sweden
2 shared publications
Latest Publications
- Open Access
- 27 March 2024
- Published by MDPI AG in Proceedings
- Vol. 100 (1) , 20
Exploring the Antimicrobial and Anticancer Potential of a Bioactive Peptide from T. radiatus: A Comprehensive Study
Therapeutic peptides have emerged as a promising frontier in the development of anti-cancer agents, classified into three main groups: antimicrobial/pore-forming peptides, cell-permeable peptides, and tumor-targeting peptides
- 27 March 2024
- Published by MDPI AG in Proceedings
- Vol. 100 (1) , 20
Open AccessExploring the Antimicrobial and Anticancer Potential of a Bioactive Peptide from T. radiatus: A Comprehensive Study
Therapeutic peptides have emerged as a promising frontier in the development of anti-cancer agents, classified into three main groups: antimicrobial/pore-forming peptides, cell-permeable peptides, and tumor-targeting peptides
- Open Access
- 27 March 2024
- Published by MDPI AG in Proceedings
- Vol. 100 (1) , 9
Optimization and Development of Magnetically Triggered Letrozole Nanoliposomes for Breast Cancer Targeting
Background: Breast cancer is one of the most frequently diagnosed cancers and is the leading cause of death among women worldwide
- 27 March 2024
- Published by MDPI AG in Proceedings
- Vol. 100 (1) , 9
Open AccessOptimization and Development of Magnetically Triggered Letrozole Nanoliposomes for Breast Cancer Targeting
Background: Breast cancer is one of the most frequently diagnosed cancers and is the leading cause of death among women worldwide
- Open Access
- 27 March 2024
- Published by MDPI AG in Proceedings
- Vol. 100 (1) , 8
Synthesis and Preliminary Investigation of Metal Nanoparticles from the Stem Extract of Bacopa sp. for the Treatment of Lung Cancer
Lung cancer is the third most common cancer in women and the most common cancer in males. Chemotherapy, allopathy, hormone therapy, radiation therapy, surgery, immune system, and targeted therapies are frequently used to treat lung cancer. These medications induce other diseases and have a variety of negative effects. Thus, we used a different strategy and sought to treat lung cancer with medicinal herbs. We selected the perennial creeping herb Bacopa monnieri, which belongs to the Scrophulariaceae family, among other medicinal herbs. It contains several active phytoconstituents, including sterols, alkaloids, flavanoids, terpenoids, and saponins. The primary component with anti-lung cancer efficacy is phytosterol, according to the components. According to the phytochemical investigation, this plant contained it. The literature review indicates that the problem is lessened by nanoparticle production. Thus, the novelty of our work is the manufacture of zinc oxide nanoparticles for the treatment of lung cancer using BM stem extracts. Researchers have been interested in ZnO material because of its huge band gap (3.37 eV) with n-type semi-conductivity and high excitonic binding energy (60 meV) with regards to the different semiconductor nanomaterials, such as TiO2, SnO2, GaN, CuO, GaAs, Si, and ZnO. Zinc oxide in bulk is economical and can be used for many different industrial processes, such as the creation of nanoparticles. Zinc acetate serves as the precursor and stem extract serves as the reducing agent in the synthesis. The absorbance peak between 300 and 400 nm in UV spectroscopy was used to characterize the ZnO nanoparticles that were produced from hydromethanolic BM stem extract. In later research, lung cancer treatment might be considered. Given that lung (A549) cell lines will be treated with phytosterol-containing hydromethanolic BM stem extract in the form of ZnO nanoparticles, which will cause cell death by reducing cell proliferation, DNA damage and apoptosis may occur.
- 27 March 2024
- Published by MDPI AG in Proceedings
- Vol. 100 (1) , 8
Open AccessSynthesis and Preliminary Investigation of Metal Nanoparticles from the Stem Extract of Bacopa sp. for the Treatment of Lung Cancer
Lung cancer is the third most common cancer in women and the most common cancer in males. Chemotherapy, allopathy, hormone therapy, radiation therapy, surgery, immune system, and targeted therapies are frequently used to treat lung cancer. These medications induce other diseases and have a variety of negative effects. Thus, we used a different strategy and sought to treat lung cancer with medicinal herbs. We selected the perennial creeping herb Bacopa monnieri, which belongs to the Scrophulariaceae family, among other medicinal herbs. It contains several active phytoconstituents, including sterols, alkaloids, flavanoids, terpenoids, and saponins. The primary component with anti-lung cancer efficacy is phytosterol, according to the components. According to the phytochemical investigation, this plant contained it. The literature review indicates that the problem is lessened by nanoparticle production. Thus, the novelty of our work is the manufacture of zinc oxide nanoparticles for the treatment of lung cancer using BM stem extracts. Researchers have been interested in ZnO material because of its huge band gap (3.37 eV) with n-type semi-conductivity and high excitonic binding energy (60 meV) with regards to the different semiconductor nanomaterials, such as TiO2, SnO2, GaN, CuO, GaAs, Si, and ZnO. Zinc oxide in bulk is economical and can be used for many different industrial processes, such as the creation of nanoparticles. Zinc acetate serves as the precursor and stem extract serves as the reducing agent in the synthesis. The absorbance peak between 300 and 400 nm in UV spectroscopy was used to characterize the ZnO nanoparticles that were produced from hydromethanolic BM stem extract. In later research, lung cancer treatment might be considered. Given that lung (A549) cell lines will be treated with phytosterol-containing hydromethanolic BM stem extract in the form of ZnO nanoparticles, which will cause cell death by reducing cell proliferation, DNA damage and apoptosis may occur.
- Open Access
- 27 March 2024
- Published by MDPI AG in Proceedings
- Vol. 100 (1) , 7
Development of Letrozole-Loaded Magnetic Nanoemulsion Used for Breast Cancer Treatment
Introduction: Emulsions are attractive delivery systems for hydrophobic drug molecules compared to hydrophilic drug molecules
- 27 March 2024
- Published by MDPI AG in Proceedings
- Vol. 100 (1) , 7
Open AccessDevelopment of Letrozole-Loaded Magnetic Nanoemulsion Used for Breast Cancer Treatment
Introduction: Emulsions are attractive delivery systems for hydrophobic drug molecules compared to hydrophilic drug molecules
- 19 May 2023
- Published by Springer Nature in International Journal of Peptide Research and Therapeutics
- Vol. 29 (4) , 1-8
Potential Anticancer Activity of Retrocyclin-3: An in vitro Study
- 19 May 2023
- Published by Springer Nature in International Journal of Peptide Research and Therapeutics
- Vol. 29 (4) , 1-8
Potential Anticancer Activity of Retrocyclin-3: An in vitro Study
- 15 July 2022
- Published by International Journal of Pharma and Bio Sciences in International Journal of Life Science and Pharma Research
- Vol. 12 (3) , L73-L79
Anti Diabetetic Activity of Illupai Ver Chooranam on Streptozotocin Diabetic Rats
Roots of Illupai (Madhuca longifolia) are mentioned for Madhumegam in Gunapadam -Mooligai (Siddha Materia Medica). The disease Madhumegam found in siddha text is correlated with Diabetes mellitus type-II. Madhuca longifolia known as Illupai in Tamil has been widely used for the treatment of diabetes. Hence, the present study aimed to demonstrate the antidiabetic effects of Illupai ver chooranam in normal and streptozotocin (STZ) induced diabetic rats. The qualitative phytochemical analysis of the chooranam showed the presence of flavonoids, glycosides, tannins, triterpenoids, polyphenols, carbohydrates, steroids, saponin and proteins. Acute toxicity studies revealed the nontoxic nature of the illupai ver chooranam up to a dose level 2000 mg/kg body weight until the end of the study period. The illupai ver chooranam (500 and 1000 mg/kg) significantly reduced (P**< 0.01) glucose levels in diabetic rats. The other biochemical parameters like cholesterol, lipid, urea, protein, liver glycogen, serum glutamate pyruvate transaminase (SGPT) and serum glutamate oxaloacetate transaminase (SGOT), were found to be reduced by the illupai ver chooranam. The histopathological results of treated groups showed the regenerative/protective effect on cells of pancreas in diabetic rats. In the oral glucose tolerance test, the illupai ver chooranam increased the glucose tolerance. The current study revealed the antidiabetic potential of illupai ver chooranam effective in hyperglycemia and that it can effectively protect against other metabolic aberrations caused by diabetes in rats, which seems to validate its therapeutic traditional use.
- 15 July 2022
- Published by International Journal of Pharma and Bio Sciences in International Journal of Life Science and Pharma Research
- Vol. 12 (3) , L73-L79
Anti Diabetetic Activity of Illupai Ver Chooranam on Streptozotocin Diabetic Rats
Roots of Illupai (Madhuca longifolia) are mentioned for Madhumegam in Gunapadam -Mooligai (Siddha Materia Medica). The disease Madhumegam found in siddha text is correlated with Diabetes mellitus type-II. Madhuca longifolia known as Illupai in Tamil has been widely used for the treatment of diabetes. Hence, the present study aimed to demonstrate the antidiabetic effects of Illupai ver chooranam in normal and streptozotocin (STZ) induced diabetic rats. The qualitative phytochemical analysis of the chooranam showed the presence of flavonoids, glycosides, tannins, triterpenoids, polyphenols, carbohydrates, steroids, saponin and proteins. Acute toxicity studies revealed the nontoxic nature of the illupai ver chooranam up to a dose level 2000 mg/kg body weight until the end of the study period. The illupai ver chooranam (500 and 1000 mg/kg) significantly reduced (P**< 0.01) glucose levels in diabetic rats. The other biochemical parameters like cholesterol, lipid, urea, protein, liver glycogen, serum glutamate pyruvate transaminase (SGPT) and serum glutamate oxaloacetate transaminase (SGOT), were found to be reduced by the illupai ver chooranam. The histopathological results of treated groups showed the regenerative/protective effect on cells of pancreas in diabetic rats. In the oral glucose tolerance test, the illupai ver chooranam increased the glucose tolerance. The current study revealed the antidiabetic potential of illupai ver chooranam effective in hyperglycemia and that it can effectively protect against other metabolic aberrations caused by diabetes in rats, which seems to validate its therapeutic traditional use.
- Open Access
- 7 March 2022
- Published by Springer Nature in Research Square
Interactions and stability of tryptophan, proline and arginine rich peptides with EGFR kinase and its anticancer activities – insilico approaches
Lung cancer is a major public health concern due to its high prevalence and mortality, and it is also the second leading cause of cancer death worldwide. Non-small cell lung cancer accounts for more than 80% of lung cancers. In recent years, the use of bioactive peptides in cancer therapy has widened the treatment regimen. They have been confirmed to selectively target and destroy cancer cells while leaving healthy cells unaffected. Furthermore, antimicrobial peptides can cause cytotoxic activity in human cancer cells by binding to negatively charged phosphatidylserine moieties on the outer surface of cancer cell plasma membranes. In the present study, we predicted the interactions of tryptophan, proline, and arginine-rich peptides with EGFR kinase and evaluated the protein-peptide complex stability through molecular dynamics simulations. From the computational study, we selected the potential peptides based on the docking score, the number of hydrogen bonds formed between the protein-peptide complexes and the stability. These results suggest that antimicrobial peptides show potential for application in lung cancer therapies.
- 7 March 2022
- Published by Springer Nature in Research Square
Open AccessInteractions and stability of tryptophan, proline and arginine rich peptides with EGFR kinase and its anticancer activities – insilico approaches
Lung cancer is a major public health concern due to its high prevalence and mortality, and it is also the second leading cause of cancer death worldwide. Non-small cell lung cancer accounts for more than 80% of lung cancers. In recent years, the use of bioactive peptides in cancer therapy has widened the treatment regimen. They have been confirmed to selectively target and destroy cancer cells while leaving healthy cells unaffected. Furthermore, antimicrobial peptides can cause cytotoxic activity in human cancer cells by binding to negatively charged phosphatidylserine moieties on the outer surface of cancer cell plasma membranes. In the present study, we predicted the interactions of tryptophan, proline, and arginine-rich peptides with EGFR kinase and evaluated the protein-peptide complex stability through molecular dynamics simulations. From the computational study, we selected the potential peptides based on the docking score, the number of hydrogen bonds formed between the protein-peptide complexes and the stability. These results suggest that antimicrobial peptides show potential for application in lung cancer therapies.
- 1 September 2021
- Published by Bentham Science Publishers Ltd. in Cardiovascular & Hematological Agents in Medicinal Chemistry
- Vol. 19 (2) , 101-117
Pharmacological Uses of the Plants Belonging to the Genus Commiphora
Natural products have a unique place in the healthcare industry. The genus Commiphora emerged as a potential medicinal source with huge benefits as evidenced through its use in various traditional and modern systems of medicine. Therefore, we aimed to prepare a concise review on the pharmacological activities and the indigenous uses of various plant species belonging to the genus Commiphora along with the structural information of various active botanical ingredients present in these plants based on the published literatures and scientific reports. To collect the published literatures on Commiphora in various journals; to study and classify the available information on the pharmacological uses and chemical constituents; and to present the gathered information as a precise review to serve as a potential reference for future research. Pharmacological and phytochemical data on Commiphora plant species were collected from various journals, books, reference materials, websites including scientific databases, etc. for compilation. This review article describes the various pharmacological properties of plants of Commiphora species viz., anti-arthritic and anti-inflammatory, anti-atherogenic, antibacterial, anti-coagulant, antidicrocoeliasis, anti-epileptic, anti-fascioliasis, anti-fungal, anti-heterophyidiasis, anti-hypercholesterolemic, anti-hyperlipidemic, anti-hypothyroidism, anti-obesity, anti-osteoarthritic, antiosteoclastogenesis, anti-oxidant, anti-parasitic, anti-pyretic, anti-schistosomiasis, anti-septic, antithrombotic, anti-ulcer, cardioprotective, COX enzyme inhibitory, cytotoxic /anti-carcinogenic/anticancer, DNA cleavage, hypotensive, inhibits lipid peroxidation, inhibits NO and NO synthase production, insecticidal, local anesthetic, molluscicidal, smooth muscle relaxant, and tick repellent activities along with toxicity studies. Furthermore, the review also included various secondary metabolites isolated from various species of Commiphora genus along with their chemical structures serving as a ready resource for researchers. We conclude that the plant species belonging to the genus Commiphora possesses abundant pharmacological properties with a huge treasure of diverse secondary metabolites within themselves. This review indicates the necessity of further in-depth research, pre-clinical, and clinical studies with Commiphora genus, which may help to detect the unidentified potential of the Commiphora plant species.
- 1 September 2021
- Published by Bentham Science Publishers Ltd. in Cardiovascular & Hematological Agents in Medicinal Chemistry
- Vol. 19 (2) , 101-117
Pharmacological Uses of the Plants Belonging to the Genus Commiphora
Natural products have a unique place in the healthcare industry. The genus Commiphora emerged as a potential medicinal source with huge benefits as evidenced through its use in various traditional and modern systems of medicine. Therefore, we aimed to prepare a concise review on the pharmacological activities and the indigenous uses of various plant species belonging to the genus Commiphora along with the structural information of various active botanical ingredients present in these plants based on the published literatures and scientific reports. To collect the published literatures on Commiphora in various journals; to study and classify the available information on the pharmacological uses and chemical constituents; and to present the gathered information as a precise review to serve as a potential reference for future research. Pharmacological and phytochemical data on Commiphora plant species were collected from various journals, books, reference materials, websites including scientific databases, etc. for compilation. This review article describes the various pharmacological properties of plants of Commiphora species viz., anti-arthritic and anti-inflammatory, anti-atherogenic, antibacterial, anti-coagulant, antidicrocoeliasis, anti-epileptic, anti-fascioliasis, anti-fungal, anti-heterophyidiasis, anti-hypercholesterolemic, anti-hyperlipidemic, anti-hypothyroidism, anti-obesity, anti-osteoarthritic, antiosteoclastogenesis, anti-oxidant, anti-parasitic, anti-pyretic, anti-schistosomiasis, anti-septic, antithrombotic, anti-ulcer, cardioprotective, COX enzyme inhibitory, cytotoxic /anti-carcinogenic/anticancer, DNA cleavage, hypotensive, inhibits lipid peroxidation, inhibits NO and NO synthase production, insecticidal, local anesthetic, molluscicidal, smooth muscle relaxant, and tick repellent activities along with toxicity studies. Furthermore, the review also included various secondary metabolites isolated from various species of Commiphora genus along with their chemical structures serving as a ready resource for researchers. We conclude that the plant species belonging to the genus Commiphora possesses abundant pharmacological properties with a huge treasure of diverse secondary metabolites within themselves. This review indicates the necessity of further in-depth research, pre-clinical, and clinical studies with Commiphora genus, which may help to detect the unidentified potential of the Commiphora plant species.
- 12 April 2021
- Published by Bentham Science Publishers Ltd. in Current Drug Research Reviews
- Vol. 13 (1) , 73-83
Repurposing of Benzimidazole Scaffolds for HER2 Positive Breast Cancer Therapy: An In-Silico Approach
Background: A newer trend has been seen recently to reuse the conventional drugs with distinct indications for the newer applications to speed up the drug discovery and development based on earlier records and safety data. Most of the non-cancerous agents could afford a little or tolerable side effects in individuals. However, the repositioning of these non-cancerous agents for successful anticancer therapy is an outstanding strategy for future anti-cancer drug development. Since more diverse and selective cancer drug targets are being discovered and developed, the approved drug collections are particularly useful to quickly identify clinically advanced anticancer drugs against those targets. Objective: Antihelminthic drugs such as Mebendazole and Albendazole (Benzimidazole class) have been reported to exhibit cytotoxicity (or anticancer activities) against several types of cancer. Therefore, this study aims to repurpose the benzimidazole scaffold for breast cancer treatment. Methods: In the present study, three hydrazone analogs having a benzimidazole motif in their structural frame were synthesized. Their in-silico binding studies against HER2 receptor (PDB ID: 4LQM) and ADMET studies were carried out using Accelrys drug discovery studio 4.1. Cytotoxicity of the synthesized compounds against HER2 overexpressed MCF-7 cell lines was determined by MTT assay. Results: One of the compounds 2-[2-(2,4-dinitrophenyl)hydrazinylidene]-2,3-dihydro-1H-benzimidazole (U1) has shown good cytotoxicity when compared to the standard Lapatinib, which is a well known HER2 inhibitor. Conclusion: Thus, the designed benzimidazole scaffold might serve as the best leads for treating breast cancer, which is additionally confirmed by performing their docking study via Accelrys discovery studio.
- 12 April 2021
- Published by Bentham Science Publishers Ltd. in Current Drug Research Reviews
- Vol. 13 (1) , 73-83
Repurposing of Benzimidazole Scaffolds for HER2 Positive Breast Cancer Therapy: An In-Silico Approach
Background: A newer trend has been seen recently to reuse the conventional drugs with distinct indications for the newer applications to speed up the drug discovery and development based on earlier records and safety data. Most of the non-cancerous agents could afford a little or tolerable side effects in individuals. However, the repositioning of these non-cancerous agents for successful anticancer therapy is an outstanding strategy for future anti-cancer drug development. Since more diverse and selective cancer drug targets are being discovered and developed, the approved drug collections are particularly useful to quickly identify clinically advanced anticancer drugs against those targets. Objective: Antihelminthic drugs such as Mebendazole and Albendazole (Benzimidazole class) have been reported to exhibit cytotoxicity (or anticancer activities) against several types of cancer. Therefore, this study aims to repurpose the benzimidazole scaffold for breast cancer treatment. Methods: In the present study, three hydrazone analogs having a benzimidazole motif in their structural frame were synthesized. Their in-silico binding studies against HER2 receptor (PDB ID: 4LQM) and ADMET studies were carried out using Accelrys drug discovery studio 4.1. Cytotoxicity of the synthesized compounds against HER2 overexpressed MCF-7 cell lines was determined by MTT assay. Results: One of the compounds 2-[2-(2,4-dinitrophenyl)hydrazinylidene]-2,3-dihydro-1H-benzimidazole (U1) has shown good cytotoxicity when compared to the standard Lapatinib, which is a well known HER2 inhibitor. Conclusion: Thus, the designed benzimidazole scaffold might serve as the best leads for treating breast cancer, which is additionally confirmed by performing their docking study via Accelrys discovery studio.
- 16 February 2021
- Published by Springer Nature in BioNanoScience
- Vol. 11 (2) , 643-647
Preparation and In-vitro Evaluation of Pantoprazole Sodium Magnetic Microspheres by Emulsion Solvent Evaporation Method
- 16 February 2021
- Published by Springer Nature in BioNanoScience
- Vol. 11 (2) , 643-647
Preparation and In-vitro Evaluation of Pantoprazole Sodium Magnetic Microspheres by Emulsion Solvent Evaporation Method